25iP-NBOMe
![]() | |
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
JSmol) | |
SMILES
| |
|
25iP-NBOMe (2C-iP-NBOMe, NBOMe-2C-iP) is a derivative of the phenethylamine hallucinogen 2C-iP, which acts as a highly potent agonist for the human 5-HT2A receptor.[1]
Toxicity and harm potential
NBOMe compounds are often associated with life-threatening toxicity and death.
NBOMe and NBOHs are regularly sold as LSD in blotter papers,[3][11] which have a bitter taste and different safety profiles.[5][2] Despite high potency, recreational doses of LSD have only produced low incidents of acute toxicity.[2] Fatalities involved in NBOMe intoxication suggest that a significant number of individuals ingested the substance which they believed was LSD,[7] and researchers report that "users familiar with LSD may have a false sense of security when ingesting NBOMe inadvertently".[5] While most fatalities are due to the physical effects of the drug, there have also been reports of death due to self-harm and suicide under the influence of the substance.[12][13][5]
Given limited documentation of NBOMe consumption, the long-term effects of the substance remain unknown.Neurotoxic and cardiotoxic actions
Many of the NBOMe compounds have high potency agonist activity at additional 5-HT receptors and prolonged activation of 5-HT2B can cause cardiac valvulopathy in high doses and chronic use.[3][8] 5-HT2B receptors have been strongly implicated in causing drug-induced valvular heart disease.[19][20][21] The high affinity of NBOMe compounds for adrenergic α1 receptor has been reported to contribute to the stimulant-type cardiovascular effects.[8]
In vitro studies, 25C-NBOMe has been shown to exhibit cytotoxicity on neuronal cell lines SH-SY5Y, PC12, and SN471, and the compound was more potent than methamphetamine at reducing the visibility of the respective cells; the neurotoxicity of the compound involves activation of MAPK/ERK cascade and inhibition of Akt/PKB signaling pathway.[4] 25C-NBOMe, including the other derivative 25D-NBOMe, reduced the visibility of cardiomyocytes H9c2 cells, and both substances downregulated expression level of p21 (CDC24/RAC)-activated kinase 1 (PAK1), an enzyme with documented cardiac protective effects.[4]
Preliminary studies on 25C-NBOMe have shown that the substance is toxic to development, heart health, and brain health in zebrafish, rats, and Artemia salina, a common organism for studying potential drug effects on humans, but more research is needed on the topic, the dosages, and if the toxicology results apply to humans. Researchers of the study also recommended further investigation of the drug's potential in damaging pregnant women and their fetus due to the substance's damaging effects to development.[22][23]Emergency treatment
Legality
United Kingdom
This substance is a
Notes
- ^ The potency of N-benzylphenethylamines via buccal, sublingual, or nasal absorption is 50- to 100-fold greater (by weight) than oral route compared to the parent 2C-x compounds.[14] Researchers hypothesize the low oral metabolic stability of N-benzylphenethylamines is likely causing the low bioavailability on the oral route, although the metabolic profile of this compounds remains unpredictable; therefore researchers state that the fatalities linked to these substances may partly be explained by differences in the metabolism between individuals.[14]
References
- S2CID 25752763.
- ^ S2CID 247764056.
- ^ PMID 30261175.
- ^ PMID 32174803.
Recently, a new class of psychedelic compounds named NBOMe (or 25X-NBOMe) has appeared on the illegal drug market. NBOMes are analogs of the 2C family of phenethylamine drugs, originally synthesized by Alexander Shulgin, that contain a N-(2-methoxy)benzyl substituent. The most frequently reported drugs from this group are 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe. NBOMe compounds are ultrapotent and highly efficacious agonists of serotonin 5-HT2A and 5-HT2C receptors (Ki values in low nanomolar range) with more than 1000-fold selectivity for 5-HT2A compared with 5-HT1A. They display higher affinity for 5-HT2A receptors than their 2C counterparts and have markedly lower affinity, potency, and efficacy at the 5-HT2B receptor compared to 5-HT2A or 5-HT2C.
- ^ S2CID 247888583.
- PMID 35530025.
- ^ PMID 31915427.
- ^ S2CID 10382311.
- ^ S2CID 25752763.
- ISSN 1923-4163.
- PMID 26378135.
- PMID 28893436.
- S2CID 4734566.
- ^ S2CID 254857910.
- PMID 28097528.
- PMID 27406128.
- PMID 25105138.
- S2CID 240583877.
- PMID 11104741.
- PMID 10617681.
- PMID 17202450.
- S2CID 255763701.
- PMID 33598409.
- ^ "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". UK Statutory Instruments 2014 No. 1106. www.legislation.gov.uk.